i2india Ventures, a technology major, is now in the process of expanding the availability of its lung-care device known as the ‘LungFlute’. The innovative medical device, which provides relief to chronic lung patients, has proven to be  successful across India.

The drug-free and easy–to-use medical device is ideal for Indian patients as it is simple-to-use, low-cost and drug-free with no side-effects.

The company is supported by leading Indian and global innovation leaders including Tata Sons, Imperial Innovations Plc UK, apart from several leading healthcare experts and investment groups. LungFlute was developed after years of clinical research in India and abroad in association with Medical Acoustics, New York after regulatory approvals.

The device uses sound-waves, generated by the patient’s breath, to naturally clear the mucous and the company stated that it was a one-of-a-kind in the world. It provides patients relief from chronic obstructive pulmonary disorder (COPD),  bronchitis, pulmonary tuberculosis, asthma, fibrosis, pneumonia and other chronic respiratory ailments. It also provides significant relief and betters the quality of life even to long-term smokers suffering from congestion.

A large number of Indians suffer from chronic pulmonary diseases, and lose their natural ability to remove mucous from their lungs. Before LungFlute, they had little recourse to gradually losing their capacity to fight or arrest disease deterioration. Now LungFlute is a self-use, therapeutic medical device which  reduces the ongoing cost-of-care by reducing medication and nebulisation requirements, due to improved bronchial health, Deepam Mishra, CEO, i2india Ventures told Pharmabiz.

The concept of bronchial hygiene in India is underdeveloped. Due to sharp rise in recent times of lung diseases and environmental dangers, our team makes considerable effort in doctor and patient education because there is need for both  preventive and chronic care solutions.
 
The company’s strategy is direct-to-doctor education and low-cost product distribution. There a number of hospitals, private clinics and private practices, recommending and prescribing LungFlute including Narayanaya Hrudayalaya (Bangalore), Apollo Hospital (several locations), Bhawgan Mahaveer Jain Hospital (Bangalore), Global Hospital (Chennai), Apollo Hospital (several), Fortis Hospital, BL Kapoor Hospital (Delhi), Metro Hoapital (Delhi), Hiranandani Hospital (Mumbai) and DNA Multispeciality Hospital (Mumbai). The acceptance has been faster in larger cities due to relative ease of patient education and doctor awareness of new technologies, he added.

The main target are patients who attain the condition of chronic lung infections. For them, maintaining bronchial hygiene becomes crucial as their natural ability to fight lung infection is compromised. Hence Lung Flute can be prescribed at any stage of the disease and has been found effective from control of sustained coughing. In fact, it is reported that flu-patients could recover from a flu infection in less than one day, virtually eliminating the bad coughing that follows most such recoveries, said Mishra.

As part of its future growth, i2i has already commenced focusing on the research  of new technologies in both healthcare and clean-technology. It is assessing remote-diagnostics and mobile-health related technologies in the healthcare space. In this regard, it is scouting for companies developing low-cost mobile-health related solutions for Indian conditions, said Mishra.